IRWD241220C22500
- 0.05
- 0.000.00%
Ironwood Pharmaceuticals Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Shareholders Can't Ignore US$5.7m Of Sales By Ironwood Pharmaceuticals Insiders
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Ironwood Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $23
Positive Outlook for Ironwood Pharmaceuticals: LINZESS Growth and Apraglutide Potential Drive Buy Rating
Ironwood Pharmaceuticals Non-GAAP EPS of $0.02 Misses by $0.08, Revenue of $91.6M Beats by $0.3M
Express News | Ironwood Pharmaceuticals Inc: Maintains Full Year 2024 Financial Guidance
GUIDANCE: (IRWD) IRONWOOD PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $350M - $375M
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q3 Revenue $91.6M
Express News | Ironwood Pharmaceuticals Q3 Adjusted Ebitda USD 26.159 Million
Ironwood Pharmaceuticals 3Q EPS 2c >IRWD
Earnings Preview: Ironwood Pharmaceuticals
Earnings Preview: IRWD to Report Financial Results Pre-market on November 07
Express News | Ironwood Pharmaceuticals To Present Analyses From Phase III STARS Trial At The American College Of Gastroenterology 2024 Annual Scientific Meeting And Postgraduate Course On Oct. 29; Findings Reinforce The Clinical Profile Of Once-weekly Apraglutide;...
Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study
Express News | Ironwood: Expects to Complete U.S. Regulatory Submission in Q1 2025
Express News | Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults With Short Bowel Syndrome With Intestinal Failure (SBS-if), According to New Stars Phase III Data From Ironwood at Acg 2024
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call